Delaware Ovarian Cancer Foundation
Like us on Facebook!
Delaware Ovarian Cancer Foundation
701 Sweetleaf Drive
Wilmington, DE 19808
United States
ph: 302-998-6889
docf5k
Below are some articles of interest about ovarian cancer; click on a title to read an article. Please contact us if you know of ovarian cancer news you would like to see posted on our website.
As news becomes available, we will keep you updated. Please check back often for new postings.
Note that articles recently posted on this website will have "(NEW)" after it so you easily can find recently posted items.**
Also check-out the DOCF Facebook page for additional items of interest.
SPECIAL NEWS...
DOCF finally makes it into the News Journal ! ! Click HERE to read the article,"Promising Screening Research for Ovarian Cancer".
DOCF Mentioned in Delaware State News . . .
Ovarian cancer symptoms can be subtle - Delaware State N... DOVER –– Locals may have noticed that since Sept. 1 streetlights in downtown Dover have been adorned with teal ribbons. The ribbons are on display in honor of Ov... | |||||||
Preview by Yahoo | |||||||
READ ALL ABOUT IT ! ! !
DOCF IN THE WOMEN'S JOURNAL . . .
Dorianne Short, DOCF Founder/President and 11-year survivor in 2015, participated in the Women's Journal October issue. The article is entitled Celebration of Life Profiles, and features several breast cancer survivors and our own ovarian cancer survivor, Dorianne Short.
Read the latest Ovarian Cancer Trends from the CDC.
DOCF Donates $50,000 to OCRF
We are very proud to announce another DOCF research donation to the Ovarian Cancer Research Foundation in 2013. Read about it in the Delaware Business Daily September 11 Issue, click HERE. Also, click on the new "Research Donations" page for details.
Dogs Detect Early Stage Ovarian Cancer
Dogs are being trained to detect ovarian cancer in its early stages. Click HERE to read the press release from Penn Vet (University of Pennsylvania), or click HERE to watch a video on the CBS website.
Late-Night Shifts May Raise Women's Risk For Ovarian Cancer
By Amir Khan, Everyday Health (March 14, 2013), "Night shift workers may be at a greater risk of developing ovarian cancer, according to a new study. However, the risk may not be as pronounced in women who describe themselves as a 'night person'."
Widespread Flaws Found in Ovarian Cancer Treatment
"Most women with ovarian cancer receive inadequate care and miss out on treatments that could add a year or more to their lives, a new study has found."
Don't miss the important information in this article by Denise Grady, The New York Times.
Understanding Chemotherapy Treatment
This National Cancer Institute pamphlet includes important information about chemotherapy, including sections to track your treatment with your doctor or nurse.
'Pap' test possible for ovarian cancer at MSNBC News, "The Pap test, which has saved tens of thousands of women from cervical cancer, might be adapted to help fight two other deadly cancers – ovarian cancer and cancer of the uterus, doctors report."
Read important update (July 24, 2014) regarding the Doxil shortage,
click HERE.
“Tiny 3D models may yield big insights into ovarian cancer“, ScienceDaily (July 27 2016), “With a unique approach that draws on 3-D printing technologies, a team of researchers is developing new tools for understanding how ovarian cancer develops in women. ” (NEW)
“Liquid biopsies offer hope for earlier treatment, better tracking of ovarian cancer“, ScienceDaily (July 20, 2016), “A promising new way to monitor and treat recurrence of ovarian cancer has been identified by researchers -- a hard-to-detect disease that claims many lives. New research finds liquid biopsies from blood tests and DNA sequencing can detect a return of ovarian cancer long before a tumor reappears. ” (NEW)
“Simplifying access to gene testing for women with ovarian cancer”, ScienceDaily (July 13, 2016), “A new streamlined approach to genetic testing for women with ovarian cancer provides testing rapidly and affordably, allowing many more patients to benefit from personalized cancer management and their relatives to benefit from cancer prevention strategies. ” (NEW)
“Presurgery chemotherapy may make advanced ovarian cancers responsive to immunotherapy”, ScienceDaily (June 15, 2016), “Metastatic ovarian cancer patients treated with chemotherapy prior to surgery had altered immune cells in their tumors, and specific alterations identified suggest that immunotherapy given after chemotherapy may help in preventing the cancer from coming back. ” (NEW)
“T-cell receptor sequencing reveals novel biomarkers for ovarian cancer”, ScienceDaily (June 6, 2016), “Researchers used deep T-cell receptor (TCR) sequencing to evaluate the clonal composition of tumor-infiltrating lymphocytes, or TILs, and identify novel prognostic biomarkers in ovarian cancer. ” (NEW)
“Study points to therapeutic target for common, aggressive ovarian cancer”,ScienceDaily (May 5, 2016), “Small, non-coding molecules called microRNAs are known to play an important role in cancer development. Researchers now have shown their significance is greater than previously thought, a finding that could lead to new therapeutic approaches for the most common and deadly form of ovarian cancer. ” (NEW)
“New gene testing technology finds cancer risks 'hiding in plain sight'”, ScienceDaily (April 28, 2016), “A new method for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate, but also increase the number of patients that are properly diagnosed. ” (NEW)
“Drug combination shuts down cancer stem cells, tumor growth in aggressive lung cancer“, ScienceDaily (March 14, 2016), “Researchers have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.”
“Small peptides attack ovarian cancer on two fronts, research shows“, ScienceDaily (March 9, 2016), “Two forms of a peptide derived from a naturally-occurring human protein can force tumors to shrink significantly in an animal model of metastatic ovarian cancer, according to a team of researchers.”
“Cancer cells eat their neighbors' 'words'“, ScienceDaily (March 7, 2016), “Cancer cells are well-known as voracious energy consumers, but even a veteran cancer-metabolism researcher was surprised by their latest exploit: Experiments in his lab show that some cancer cells get 30-60 percent of their fuel from eating their neighbors' 'words.'”
“Alternative route for cell death revealed by scientists“, ScienceDaily (March 3, 2016), “A new pathway for mitochondrial cell death that involves the protein BCL-2 ovarian killer otherwise known as BOK has been revealed by scientists. The discovery may lead to new ways to trigger cell death in some types of cancer cells, they report.”
“New report finds 'surprising gaps' in knowledge of ovarian cancers“, ScienceDaily (March 2, 2016), “Ovarian cancer should not be categorized as a single disease, but rather as a constellation of different cancers involving the ovary, yet questions remain on how and where various ovarian cancers arise, says a new congressionally mandated report.”
“Research on treatments for advanced ovarian cancer“, ScienceDaily (February 26, 2016), “New research supports the use of weekly chemotherapy without bevacizumab in treating advanced ovarian cancer.”
“Pairing pain medicine with metal ions to battle cancer“, ScienceDaily (February 17, 2016), “Fighting chemoresistant cancer remains a huge challenge that scientists are tackling from as many angles as they can. One alternative approach involves pairing two groups of compounds -- pain medicine and metal ions -- that have individually shown promise as anti-cancer agents. Scientists now report that combining the two led to new compounds that could destroy drug-resistant cancer cells and leave most normal cells alone in lab tests.”
“A new method to improve the pre-operative diagnosis of ovarian cancer based on ultrasound“, ScienceDaily (January 19, 2016), “In a landmark study, investigators from Europe propose a new and simple method to assess the risk of malignancy of women with an adnexal mass. The method identified between 89-99 percent of patients with ovarian cancer using the results of ultrasound examination, which can be obtained in referral and non-referral centers. The work is based on the 'Simple Rules' criteria developed by the International Ovarian Tumor Analysis group to improve accurate diagnosis of ovarian cancer before surgery.”
“New gene fault behind ovarian cancer found by scientists“, ScienceDaily (January 18, 2016), “Women who carry an inherited fault in the gene BRIP1 are over three times more likely to develop ovarian cancer than those without the fault, according to a new study. Around 18 women in every 1,000 develop ovarian cancer, but this risk increases to around 58 women in every 1,000 for women with a fault in the BRIP1 gene.”
“New findings may enhance PARP inhibitors therapy in breast cancer“, ScienceDaily (January 18, 2016), “PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers, new research shows.”
“Loss of enzyme promotes tumor progression in endometrial cancer“, ScienceDaily (December 7, 2015), “Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression. CD73 is the crucial enzyme for generating adenosine, a signaling molecule important for regulation of normal tissue function and stability or homeostasis.”
“Ovarian follicles used to preserve fertility“, ScienceDaily (December 3, 2015), “A potential new approach to fertility preservation for young cancer patients has been discovered, which addresses concerns about beginning cancer treatment immediately and the possibility of reintroducing cancer cells during the fertility preservation process.”
“Novel nanoparticles for image-guided phototherapy could improve ovarian cancer treatments“, ScienceDaily (October 29, 2015), “Scientists are investigating a biodegradable nanomedicine that can selectively destroy ovarian cancer cells left behind after surgery. These findings are a step forward in the development of targeted therapies for hard-to-treat cancers.”
“Research explains limits of cancer immunotherapy drugs“, ScienceDaily (October 26, 2015), “Molecular changes within a tumor have been revealed by a team of scientists that suggests that they are preventing immunotherapy drugs from killing off the cancer.”
“Breast, ovarian cancer risk may have association with sense of smell“, ScienceDaily (October 21, 2015), “For the first time, researchers have noted that the estrous cycle (the equivalent of human menstrual cycle) in mice carrying a mutation known to cause familial predisposition to breast and ovarian cancer in humans is more readily stimulated by scent than in normal mice. Even more surprising was the finding that the ovary, independently of the nose, mediated the olfactory signals.”
“Special class of T cells shown to both attack cancer cells and enlist other immune cells“, ScienceDaily (October 15, 2015), “New insights about a subset of T cells has been shared by researchers, that suggest that they appear to both inhibit cancer growth and enhance the tumor-killing powers of other immune cells.”
“BRCA1 Deficiency Increases Sensitivity of Ovarian Cancer Cells to Auranofin”, ScienceDaily (January 8, 2016), “An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study has found. Auranofin is currently undergoing trials for repurposing to treat recurrent epithelial ovarian cancer, which makes up around 90 per cent of diagnosed ovarian cancers.”
“Scientists Test New Strategy That Could Help Fight Ovarian Cancer”, ScienceDaily (January 6, 2016), “A promising novel method to treat gynecologic tumors has been discovered by researchers. The approach focuses on a protein called p53, which is commonly mutated in women who have high-grade serous ovarian cancer, the deadliest form of reproductive cancer. In many women with the disease, the cancer is very advanced by the time it is diagnosed and is therefore difficult to treat.”
“Long-Term Outcomes of Preventing Premature Menopause During Chemotherapy”, ScienceDaily (December 22, 2015), “Compared with receiving chemotherapy alone, women with breast cancer who also received the hormonal drug triptorelin to achieve ovarian suppression had a higher long-term probability of ovarian function recovery, without a statistically significant difference in pregnancy rate or disease-free survival, according to a study.”
“Fallopian Tube Organoids Promise Better Understanding of Ovarian Cancer, Infertility”, ScienceDaily (December 11, 2015), “A new way of growing fallopian tube cells in culture is expected to give a boost to our understanding and prevention of female genital diseases, such as infertility, inflammatory disease, and ovarian cancer.”
“Obesity Contributes to Metastasis in Ovarian Cancer Patients”, ScienceDaily (December 7, 2015), “An increased body mass index is associated with a greater risk for ovarian cancer with worse overall survival, a large number of studies have shown. However, the influence of obesity on ovarian cancer metastasis had not been evaluated. Researchers set out to determine whether obesity contributes to ovarian cancer metastatic success. In other words, are tumor cells better able to successfully metastasize when the "host" is obese versus lean?”
“New Method Enables the Early Detection of Ovarian Cancer”, ScienceDaily (November 10, 2015), “Around 75 per cent of ovarian tumors arise from the fallopian tube. There are currently no options for detecting this condition early or preventing it. With the help of an innovative, "three-way" catheter, a new study suggests that this situation may be different in the future.”
“Different Types of Ovarian Cancer Have Different Causes”, ScienceDaily (November 2, 2015), “The more children a woman has or whether a woman has had her fallopian tubes cut lowers the risk of different types of ovarian cancer to different levels, according to new research."
“Sniffing out Cancer with Improved 'Electronic Nose' Sensors”, ScienceDaily (September 30, 2015), “Scientists have been exploring new ways to 'smell' signs of cancer by analyzing what's in patients' breath. In a new study, one team now reports new progress toward this goal. The researchers have developed a small array of flexible sensors, which accurately detect compounds in breath samples that are specific to ovarian cancer.”
“Hormone Replacement Therapy Safe, Perhaps Beneficial in Women Treated for Ovarian Cancer, Major Trial Shows”, ScienceDaily (September 28, 2015), “Women with the most common type of ovarian cancer can safely take hormone replacement therapy (HRT), and it could have a beneficial effect on their survival, a long-term clinical trial reports. The 24-year, phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer -- which accounts for 80-90 per cent of cases -- can safely take HRT during or after their treatment.”
“Researchers Isolate Possible Ovarian Cancer Biomarkers”, ScienceDaily (September 16, 2015), “Researchers have utilized a highly sensitive mass spectrometry analysis to identify and measure difficult-to-detect N-glycan biomarkers associated with ovarian cancers in stages I-IV. In a surprising finding, the researchers determined that the level of biomarkers associated with ovarian cancer does not simply increase or decrease over the course of the disease, but can rise and fall during different stages."
“Cancer Preventative Surgery Could Become a Thing of the Past, New Research Suggests”, ScienceDaily (September 10, 2015), “Two new studies looking at the effect the menstrual cycle has on the development of breast and ovarian cancer reveal alternative prevention strategies that may render surgery unnecessary.”
“Advance in photodynamic therapy offers new approach to ovarian cancer”, ScienceDaily (August 13, 2015), “Researchers have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors."
“Gene therapy may improve survival of patients with recurrent ovarian cancer”, ScienceDaily (July 27, 2015), “Use of gene therapy to deliver a protein that suppresses the development of female reproductive organs may improve the survival of patients with ovarian cancer that has recurred after chemotherapy, which happens 70 percent of the time and is invariably fatal.”
“Important molecule in ovarian cancer”, ScienceDaily (July 22, 2015), “An important new target for ovarian cancer therapy has been identified by scientists. Contrary to current research, this new study found that LKB1 is an important molecule in the cancer's promotion and survival. Their research definitively shows that ovarian cancer cells still have LKB1 and that this molecule allows ovarian cancer spheroids to change their metabolism, promote tumor cell survival and make them more resistant to chemotherapy.”
“Cancer drug 49 times more potent than Cisplatin”, ScienceDaily (July 7, 2015), “A new cancer drug has been found to have effectiveness for ovarian and bowel cancer that is 49 times as potent is Cisplatin. The key to this new drug, researchers report, is that it can shut down a cancer cell's metabolism. They add that the new drug could be cheaper to produce and less harm to healthy cells than alternative therapies.”
“Body mass index impacts ovarian cancer chemotherapy dosages”, ScienceDaily (July 2, 2015), “Ovarian cancer patients who are overweight or obese are often given less chemotherapy per pound of body weight in order to reduce the toxic side effects associated with higher doses, and this in turn may lower their chances of survival, according to a new study.”
“Experimental drug combined with standard chemo may shrink treatment-resistant ovarian cancers, animal study shows”, ScienceDaily (July 1, 2015), “Working in cell cultures and mice, researchers have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel.”
“Scientists find genetic variants key to understanding origins of ovarian cancer”, ScienceDaily (June 15, 2015), “New research is bringing the origins of ovarian cancer into sharper focus. The study highlights the discovery of three genetic variants associated with mucinous ovarian carcinomas (MOCs), offering the first evidence of genetic susceptibility in this type of ovarian cancer.”
“Theranostic PET takes on both ovarian and prostate cancer”, ScienceDaily (June 8, 2015), “A first-in-human study shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells for both imaging and personalized cancer treatment.”
“New technique could pick up twice as many women with ovarian cancer screening “, ScienceDaily (May 4, 2015), “A new screening method can detect twice as many women with ovarian cancer as conventional strategies, according to the latest results from the largest trial of its kind. The new method detected cancer in 86 percent of women with invasive epithelial ovarian cancer, whereas the conventional test used in previous trials or in clinical practice would have identified fewer than half of these women (41 percent or 48 percent respectively).”
”Earlier ovarian cancer detection”, ScienceDaily (April 20, 2015), “Successful ovarian cancer treatment often relies on catching it early. A study may help point to a new method for women at risk."
”Investigational personalized cellular therapy tolerated well by patients with advanced mesothelioma, ovarian and pancreatic cancers”, ScienceDaily (April 19, 2015), “Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers. The data adds to a growing body of research showing the promise of CAR T cell technology."
”Immunotherapy delays recurrence for stage III and IV ovarian cancers”, ScienceDaily (March 28, 2015), “Medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman’s tumor and extend the time period between initial treatment and the cancer’s return.”
”Women with ovarian cancer gain extra months with addition of drug to standard chemotherapy”, ScienceDaily (March 28, 2015), ”Overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone."
”Cancer research breakthrough: Immune markers discovered that can predict ovarian cancer patients' response to treatment”, ScienceDaily (March 24, 2015), “A biomarker that will help lead to better predictions of the success of chemotherapy in ovarian cancer patients has been discovered by researchers. This discovery could lead to better treatment options in the fight against ovarian cancer, they say.”
“New method shrinks metastatic ovarian cancer and reduces chemotherapy dose”, ScienceDaily (February 2, 2015), “New research may eventually help improve the five-year survival rate of ovarian cancer patients by describing a new way of shrinking ovarian cancer tumors while also simultaneously improving drug delivery, scientists report."
“Hormone-Blocking Drug Prevents Ovarian Failure, Improves Fertility in Breast Cancer Patients “, ScienceDaily (March 4, 2015), “Breast cancer patients who are given the hormone-blocking drug goserelin during chemotherapy are less likely to experience ovarian failure and more likely to have successful pregnancies, according to results from a recent study.”
“Ovarian Cancer: Chemotherapy and Improved Surgical Techniques”, SciencyDaily (March 9, 2015), “Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. In 2015, it is estimated that more than 21,000 new diagnoses and more than 14,000 deaths from this neoplasm will occur in the United States; less than 40 percent of women with ovarian cancer are cured."
“Anderson Algorithm Increases Surgical Success with Advanced Ovarian Cancer”, ScienceDaily (February 27, 2015), “A surgical algorithm developed and implemented by ovarian cancer specialists dramatically increases the frequency of complete removal of all visible tumor – a milestone strongly tied to improved survival. The algorithm is a framework for a personalized surgical approach that allows surgeons to be "much smarter about whom we operate on up front, providing a more individualized approach to surgery that's led to better results for our patients," said one clinician.”
"Patchwork' Ovarian Cancer More Deadly”, ScienceDaily (February 24, 2015), “The most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to a new study. Serous ovarian cancers containing a variety of genetically-different cells were more likely to become resistant to treatment and come back again than cancers made of more similar cells. Women with this type of tumor also died sooner than those with less varied tumors.”
"New Therapeutic Strategy Discovered for Ovarian Cancer”, ScienceDaily (February 16, 2015), “Ovarian cancer is the deadliest of all cancers affecting the female reproductive system with very few effective treatments available. Prognosis is even worse among patients with certain subtypes of the disease. Now, researchers have identified a new therapeutic target in a particularly aggressive form of ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease.”
"A One-Two Punch Against Ovarian Cancer", ScienceDaily (February 9, 2015), "Only 1.3 percent of cancers diagnosed between 2004 and 2010 were cancers of the ovary, but fewer than half of these women survived for five years or more. Researchers have now studied a combination therapy developed to help women with ovarian cancer."
“Researchers reprogram tumor's cells to attack itself”, ScienceDaily (February 3, 2015), “Inserting a specific strain of bacteria into the microenvironment of aggressive ovarian cancer transforms the behavior of tumor cells from suppression to immunostimulation, researchers have found.”
“FDA approves Lynparza to treat advanced ovarian cancer”
“First LDT companion diagnostic test also approved to identify appropriate patients”
FDA News Release (December 19, 2014), “The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.”
“Anti-leukemia drug may also work against ovarian cancer”, ScienceDaily (November 17, 2014), “An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia may also prove effective against ovarian cancer – and likely other cancers as well, report researchers.”
“Scientists find way to reduce ovarian cancer tumors, chemo doses”, ScienceDaily (November 13, 2104), “In a potential breakthrough against ovarian cancer, researchers have discovered how to both shrink tumors and improve drug delivery, allowing for lower doses of chemotherapy and reducing side effects.”
“Tea, citrus products could lower ovarian cancer risk, new research finds”, ScienceDaily (October 28, 2014), “Tea and citrus fruits and juices are associated with a lower risk of developing ovarian cancer, according to new research. The research reveals that women who consume foods containing flavonols and flavanones (both subclasses of dietary flavonoids) significantly decrease their risk of developing epithelial ovarian cancer, the fifth-leading cause of cancer death among women.”
“Ovarian Cancer DNA Detected in Vaginal Fluid”, WebMD News from HealthDay, by Amy Norton, HealthDay Reporter (October 7, 2014), “Preliminary finding may bring doctors one step closer to test that could catch the disease in early stages. Researchers have found it's possible to detect ovarian cancer gene mutations in vaginal fluid samples -- a finding they hope is a step toward an effective screening test for the disease.”
“A way to kill chemo-resistant ovarian cancer cells: Cut down its protector”, ScienceDaily (September 24, 2014), “Ovarian cancer is the most deadly gynecological cancer, claiming the lives of more than 50 percent of women who are diagnosed with the disease. A new study provides new insight into why ovarian cancer is often resistant to chemotherapy, as well as a potential way to improve its diagnosis and treatment.”
“Breakthroughs made in ovarian cancer research”, ScienceDaily (August 8, 2014), “New clues to early detection and personalized treatment of ovarian cancer have been made by researchers. Ovarian cancer is currently one of the most difficult cancers to diagnose early due to the lack of symptoms that are unique to the illness. Successful treatment is difficult at this late stage, resulting in high mortality rates.”
"New route for ovarian cancer spread discovered", ScienceDaily (July 14, 2014), "Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, scientists report. The researchers found the circulating tumor cells (CTCs) rely on HER3, a less-famous sibling of the HER2 receptor protein prominent in some breast cancers, to find their way to the omentum, a sheet of tissue that covers and supports abdominal organs."
"No link between fertility drugs and breast, ovarian, uterine cancers, study finds", ScienceDaily (June 30, 2014), "There is 'little evidence' that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a substantial 30-year follow-up study. The study was a retrospective investigation involving 12,193 women treated for infertility between 1965 and 1988 at five US sites. A total of 9,892 women were successfully followed for cancer outcomes."
"Ovarian cancer cells more aggressive on soft tissues", ScienceDaily (May 8, 2014), "When ovarian cancer spreads from the ovaries it almost always does so to a layer of fatty tissue that lines the gut. A new study has found that ovarian cancer cells are more aggressive on these soft tissues due to the mechanical properties of this environment. The finding is contrary to what is seen with other malignant cancer cells that seem to prefer stiffer tissues."
"New route for ovarian cancer spread discovered", ScienceDaily (July 14, 2014), "Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, scientists report. The researchers found the circulating tumor cells (CTCs) rely on HER3, a less-famous sibling of the HER2 receptor protein prominent in some breast cancers, to find their way to the omentum, a sheet of tissue that covers and supports abdominal organs."
“Ovarian cancer treatment discovered by researchers”, ScienceDaily (June 19, 2014), “A new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur, research shows. In addition, this breakthrough showed a trend in improving survival although these data are not yet mature. "This is an exciting new targeted medication in treating recurrent ovarian cancer. Recurrent ovarian cancer is almost always fatal and new treatments are desperately needed," said one researcher.”
“Common, Hard-To-Treat Cancers: Potential New Targeted Therapies”, ScienceDaily (June 2, 2014), “Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted recently by researchers. Findings from the mid- and late-stage trials suggest new ways to slow disease progression and improve survival for patients who experience relapses or resistance to available treatments.”
“Drug Combination may be Highly Effective in Recurrent Ovarian Cancer”, ScienceDaily (June 1, 2014),”Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer has been identified by recent research. The trial compared the activity of the combination of the drug olaparib, which blocks DNA repair, and the blood vessel inhibitor drug cediranib, vs. olaparib alone. Trial results showed a near doubling of progression-free survival benefit for the combination therapy over use of the single drug alone.”
“Heredity is not destiny: Breastfeeding, birth control pills may reduce ovarian cancer risk among women with BRCA gene mutations”, ScienceDaily (May 14, 2014), “Breastfeeding, tubal ligation – also known as having one’s “tubes tied” – and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis. Though the team cautions that more data are required before definitive conclusions about these variables can be made, the findings help to shed light on non-surgical risk reduction options for women who may not be ready to undergo prophylactic removal of their ovaries to cut their cancer risk.”
“Ovarian cancer cells more aggressive on soft tissues”, ScienceDaily (May 8, 2014), “When ovarian cancer spreads from the ovaries it almost always does so to a layer of fatty tissue that lines the gut. A new study has found that ovarian cancer cells are more aggressive on these soft tissues due to the mechanical properties of this environment. The finding is contrary to what is seen with other malignant cancer cells that seem to prefer stiffer tissues.”
“Common Cancers Evade Detection By Silencing Parts Of Immune System Cells”, ScienceDaily (March 4, 2014), “A set of genes has been identified that appear to predict which tumors can evade detection by the body’s immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.”
"Genetic Cause Of Rare Type Of Ovarian Cancer Discovered”, ScienceDaily (March 23, 2014), “The cause of a rare type of ovarian cancer that most often strikes girls and young women has been uncovered by an international research team, according to a study.”
“New Ovarian Cancer Targets Proposed: Proteins Called TAFs”, ScienceDaily (March 13, 2014), “Proteins called TAFs were once thought to be generic cogs in the machinery of gene expression, but in a new study, scientists propose that they may be important suspects in the progression of ovarian cancer that should not continue to be overlooked.”
“Novel Cancer Vaccine Holds Promise Against Ovarian Cancer, Mesothelioma”, ScienceDaily (March 5, 2014), “A novel approach to cancer immunotherapy may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma.”
“Fast, Effective Mechanism To Combat An Aggressive Cancer”, ScienceDaily (February 24, 2014), “A new strategy to tackle an aggressive subtype of ovarian cancer using a new nanoscale drug-delivery system designed to target specific cancer cells has been developed.”
“Preventive Ovarian Surgery Should Be Performed Early For Greatest Benefit; Substantial Mortality Risk Reduction Found”, ScienceDaily (February 24, 2014), “Women with BRCA1 mutations should have preventive ovarian surgery (prophylactic oophorectomy) by age 35, as waiting until a later age appears to increase the risk of ovarian cancer before or at the time of the preventive surgery.”
“New Study Shows Promise For Preventing Therapy Resistance In Tumor Cells”, ScienceDaily (January 9, 2014), “A new study suggests that activating the tumor suppressor p53 in normal cells causes them to secrete Par-4, another potent tumor suppressor protein that induces cell death in cancer cells.”
“Researchers Discover Ovarian Cancer Biomarker”, ScienceDaily (January 8, 2014), “Researchers have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer – a breakthrough that has the potential to improve outcomes for patients with the disease. ”
"Clinical Waste may be Valuable for Monitoring Treatment Response in Ovarian Cancer", ScienceDaily (December 6, 2013), "A microchip-based device developed may greatly simplify the monitoring of patients' response to treatment for ovarian cancer -- the most lethal form of gynecologic cancer -- and certain other malignancies."
"Investigational PARP Inhibitor Promising in BRCA- Related Cancers", ScienceDaily (October 22, 2013), "An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results."
"Nanotech System, Cellular Heating may Improve Treatment of Ovarian Cancer", ScienceDaily (October 17, 2013), "The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers report in a new study."
"Targeted Treatment plus Chemotherapy Could Benefit Women with Ovarian Cancer", ScienceDaily (October 11, 2013), "Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows."
"AZ, Merck Announce Licensing Deal for Potential Treatment for Ovarian Cancer", Delaware Business Daily (September 13, 2013),"MK-1775 is designed to cause certain tumor cells to divide without undergoing the normal DNA repair processes, ultimately leading to cell death. Early evidence suggests that the combination of MK-1775 and chemotherapy agents can enhance anti-tumor properties, in comparison to chemotherapy alone."
"Cancer Cells Appear to Change While Moving Throughout Body", ScienceDaily (August 12, 2013), "Scientists now have direct evidence that cancer cells appear to change while moving through the body, at least in ovarian cancer patients. The findings suggest that doctors should treat patients with a combination of drugs: those that kill cancer cells in primary tumors and drugs that target the unique characteristics of cancer cells spreading through the body."
"Engineered Oncolytic Herpes Virus Inhibits Ovarian and Breast Cancer Metastases", ScienceDaily (February 1, 2013), "A genetically reprogrammed Herpes simplex virus (HSV) can cure metastatic diffusion of human cancer cells in the abdomen of laboratory mice, according to a new study."
"DNA Marker Indicates if Ovarian Cancer Treatment will be Successful, Study Suggests", ScienceDaily (April 3, 2012), "Researchers have discovered that blood can help determine the best treatment plan for patients with ovarian cancer."
"New Screening Strategy May Catch Ovarian Cancer at Early Stages", ScienceDaily (August 26, 2013), "A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal."
"Engineered Oncolytic Herpes Virus Inhibits Ovarian and Breast Cancer Metastases",ScienceDaily (February 1, 2013), "A genetically reprogrammed Herpes simplex virus (HSV) can cure metastatic diffusion of human cancer cells in the abdomen of laboratory mice, according to a new study."
"Comprehensive List of Gene Variants Developed for Cancer Cells from Nine Tissue Types", ScienceDaily (July 15, 2013), "Scientists have developed a comprehensive list of genetic variants for each of the types of cells that comprise what is known as the NCI-60 cell line collection. This new list adds depth to the most frequently studied human tumor cell lines in cancer research, molecular pharmacology, and drug discovery."
"New Resistance Mechanism to Chemotherapy in Breast and Ovarian Cancer, ScienceDaily (June 18, 2013), “A new study explains why tumors with BRCA1 and BRCA2 mutations stop responding to PARP inhibitor drugs.”
"Women Beware: Most Feminine Hygiene Products Contain Toxic Ingredients", from Mercola.com (May 22, 2013), “The issue of what kind of feminine hygiene products you use is rarely if ever discussed. Yet it’s clearly an important topic for every woman out there."
"More Research Verifies Powerful Anti-Cancer Properties of Turmeric", from NaturalNews.com (May 3, 2013), By David Gutierrez, staff writer, “A growing body of research continues to pile up, showing that turmeric and its naturally occurring compounds have potent anti-cancer properties."
"Screening Detects Ovarian Cancer Using Neighboring Cells", ScienceDaily (April 22, 2013), “Pioneering biophotonics technology detects the early presence of ovarian cancer in humans by examining cells easily brushed from the neighboring cervix or uterus, not the ovaries themselves. The results have the potential to translate into a minimally invasive early detection method using cells collected by a swab, exactly like a pap smear.”
"Discovery Brings Hope of New Tailor-Made Anti-Cancer Agents", ScienceDaily (April 21, 2013), “Scientists have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients. The development of the compound, called WEHI-539, is an important step towards the design of a potential new anti-cancer agent.”
“Two-Step Ovarian Cancer Immunotherapy Made From Patients' Own Tumor Benefits Three Quarters of Trial Patients”, ScienceDaily (April 7, 2013), “As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according to new research.”
“Engineered T Cells Kill Tumors but Spare Normal Tissue in an Animal Model”, ScienceDaily (April 7, 2013), “Researchers devised a next gen cancer immune approach in which the activation signal for T cells is physically dissociated from a second costimulatory signal for immune cells. The two CARs carry different antigen specificity -- mesothelin and a-folate receptor. Mesothelin is primarily associated with mesothelioma and ovarian cancer, and a-folate receptor with ovarian cancer.”
“Cisplatin-Resistant Cancer Cells Sensitive to Experimental Anticancer Drugs Called PARP Inhibitors”, ScienceDaily (April 3, 2013), “Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study.”
“New DNA Sequences Home in on Breast, Ovarian Cancer Risk”, ScienceDaily (March 20, 2013), “Researchers have identified new DNA sequences associated with breast cancer -- the most common cancer among women, with an average risk of developing the disease of 10 percent -- and ovarian cancer, the most common cause of death from gynecological cancers in the U.S. The findings will help reveal the underlying causes of these diseases and help researchers build better risk models to support new prevention strategies.”
"Origin of Aggressive Ovarian Cancer Discovered", ScienceDaily (March 6, 2013), "Researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States."
"Protein That May Control the Spread of Cancer Discovered", ScienceDaily (February 26, 2013), "Researchers have uncovered a novel mechanism that may lead to more selective ways to stop cancer cells from spreading. Cancer biologists have identified the role of the protein RSK2 in cancer cell migration, part of the process of cancer metastasis."
"BRCA mutation carriers have little long-term survival benefit with ovarian cancer, researchers say", ScienceDaily (February 14, 2013), "Researchers studied the long-term survival of women with a BRCA1 or BRCA2 gene mutation who were diagnosed with invasive ovarian cancer. They found that the short-term benefit to having either mutation does not lead to a long-term survival benefit."
"Deep genomic analysis identifies a micro RNA opponent for ovarian cancer", ScienceDaily (February 11, 2013), "Researchers employed an extensive analysis of genomic information to identify a new, high-risk cohort of ovarian cancer patients, characterize their tumors, find a potential treatment and test it in mouse models of the disease." |
"Study prompts rethink of how ovaries develop", ScienceDaily (February 11, 2013), "New research will rewrite the textbooks on how an ovary is formed, as well as providing new insights into women's health and fertility." "Two-step immunotherapy attacks advanced ovarian cancer", ScienceDaily (January 31, 2013), "Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers show that a two-step personalized immunotherapy treatment -- a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy -- triggers anti-tumor immune responses in these type of patients." "New method to diagnose hereditary breast and ovarian cancer", ScienceDaily (January 16, 2013), "Researchers have developed and validated a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The model is based on a genetic and bioinformatic analysis which has been proved very effective." |
"Common Diabetes Drug May Treat Ovarian Cancer", ScienceDaily (December 3, 2012), "Diabetic patients with ovarian cancer who took the drug metformin for their diabetes had a better survival rate than patients who did not take it, a study headed by Mayo Clinic shows. The findings, published early online in the journal Cancer, may play an important role for researchers as they study the use of existing medications to treat different or new diseases."
"Advances in Understanding of the Mechanisms of Drug Resistance to Dual-Agent Chemotherapy in Recurrent Ovarian Cancer", ScienceDaily (November 30, 2012), "More than half of all patients with ovarian cancer experience recurrent disease and will eventually fail to respond to chemotherapy. The failure of chemotherapy is usually due to the development of resistance to the two main classes of chemotherapy agents used to fight it -- platinating agents and taxanes. Now, a study reported in the open-access Journal of Ovarian Research provides novel information that further adds to clinicians' understanding of the mechanisms involved in the development of resistance to dual-agent chemotherapy."
"Novel Mechanism Through Which Normal Stromal Cells Become Cancer-Promoting Stromal Cells Identified", ScienceDaily (November 21, 2012), "New understanding of molecular changes that convert harmless cells surrounding ovarian cancer cells into cells that promote tumor growth and metastasis provides potential new therapeutic targets for this deadly disease, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research."
"Squeezing Ovarian Cancer Cells to Predict Metastatic Potential: Cell Stiffness as Possible Biomarker", ScienceDaily (October 20, 2012), "New Georgia Tech research shows that cell stiffness could be a valuable clue for doctors as they search for and treat cancerous cells before they're able to spread."
"Aspirin May Help Prevent Ovarian Cancer", by Christine Kearney, Medical News Today (October 10, 2012), "Women who use aspirin on a regular basis have a lower risk of developing serous ovarian cancer...".
"New Chemotherapy Strategy Emerges in Ovarian Cancer", by Anita T. Shaffer, on OncLive.com (September 24, 2012), "A study evaluating first-line chemotherapy dosing strategies for treating patients with advanced epithelial ovarian cancer has delivered practice-changing findings...".
"Researchers Find Possible Key to Regulation of Ovarian Cancer Stem Cells", ScienceDaily (September 27, 2012), "Evidence suggests that cancer stem cells are responsible for cancer initiation, progression, metastasis, chemoresistance and relapse."
"Ovarian Cancer Screening: Simple Two-Minute Questionnaire That Checks for Six Warning Signs May Lead to Better Early Detection", ScienceDaily (September 21, 2012), Read how this simple questionnaire could help with early detection of ovarian cancer.
"Lack of Oxygen in Cancer Cells Leads to Growth and Metastasis", ScienceDaily (September 13, 2012), "It seems as if a tumor deprived of oxygen would shrink. However, numerous studies have shown that tumor hypoxia, in which portions of the tumor have significantly low oxygen concentrations, is in fact linked with more aggressive tumor behavior and poorer prognosis."
"Ovarian Cancer Cells Hijack Surrounding Tissues to Enhance Tumor Growth, ScienceDaily (September 4, 2012), Tumor growth is dependent on interactions between cancer cells and adjacent normal tissue, or stoma. Stromal cells can stimulate the growth of tumor cells.
"Project Achilles Pinpoints Vulnerabilities in Ovarian Cancer; Genome-Scale Study of 100 Cell Lines Reveals Cancers' Dependencies", ScienceDaily (July 11, 2011), Researchers examined the cells of 100 tumors, including 25 ovarian cancer tumors to find weak spots in genes upon which cancer depends.
"Discovery May Lead to Turning Back the Clock On Ovarian Cancer", ScienceDaily (Feb. 11, 2011), "Cancer researchers have discovered that a type of regulatory RNA may be effective in fighting ovarian cancer."
"First-Of-Its-Kind Approach Nanomedicine Design Effectively Targets Cancer With Decreased Toxicity", ScienceDaily (July 10, 2012), Researchers at Brigham and Women's Hospital (BWH) are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment."
"Is it Ovarian Cancer or IBS?", by Kristen Stewart on EverydayHealth.com. "Ovarian cancer and irritable bowel syndrome, or IBS, share many symptoms. Learn why the wrong diagnosis may be made." Read more by clicking the title link.
"Endometriosis Could Raise Risk of 3 Ovarian Cancers", by Kristen Stewart on EverydayHealth.com (02/22/2012). "Increased screening advised for women with uterine disorder, study says." Read more by clicking the title link.
"Ovarian Cancer Vaccine Give Patients Hope", Check out the video or read about this important breakthrough at CBS.
"ASCO: Ovarian Ca Recurrence Yields to PARP Inhibitor", by Charles Bankhead (06/09/2011) from medpagetoday.com.
"ASCO: Abagovomab No Help in Ovarian Cancer", by Ed Susman (06/08/2011) from medpagetoday.com
"CA-125 Change Over Time Shows Promise as Screening Tool for Early Detection of Ovarian Cancer", MD Anderson News Release (05/20/2010) on mdanderson.org
"Curcumin Pretreatment Helps Destroy Ovarian Cancer Cells", submitted by Kathleen Blanchard RN (05/03/2010) on EmaxHealth.com
"Flaxseed-Fed Chickens Shed Light on Ovarian Cancer", Science Daily (May 11, 2010)
"Curcumin Induces Chemo/Radio-Sensitization in Ovarian Cancer Cells and Curcumin Nanoparticles Inhibit Ovarian Cancer Cell Growth", from the Journal of Ovarian Research (03/11/2010), Yallapu et al.
"MCP: Researchers Reveal Potential Biomarker for Ovarian Cancer", press release courtesy of the Biodesign Institute at Arizona State University, on asbmb.org
“Discoveries offer hope for managing ovarian cancer“, ScienceDaily (July 28, 2016), “A protein discovery offers a possible test for ovarian cancer, report scientists. The research team also identified an enzyme vital to ovarian cancer growth and spread, offering a target for new treatments. In ovarian cancer, early detection and treatment are vital; this research offers routes to both." (NEW)
“T-cells can be directed to treat a variety of ovarian cancers“, ScienceDaily (July 28, 2016), “Scientists have discovered a receptor-protein that is expressed on the surface of different types of ovarian tumor cells, including clear cell and mucinous ovarian tumors, two of the most aggressive subtypes of the disease. The protein is not found on non-ovarian healthy tissues in adult women, meaning that this protein could represent a highly specific therapeutic target in a range of ovarian tumors.” (NEW)
“BRCA1 mutations in breast, ovarian cancer can predict treatment resistance”, ScienceDaily (July 25, 2016), “Two new studies have investigated the mechanisms underlying the treatment resistance associated with some BRCA1 mutations, and the findings provide information that may help predict which treatments will be effective in women with breast and ovarian cancer.” (NEW)
“BRCA1 mutations in breast, ovarian cancer can predict treatment resistance”, ScienceDaily (July 25, 2016), “Two new studies have investigated the mechanisms underlying the treatment resistance associated with some BRCA1 mutations, and the findings provide information that may help predict which treatments will be effective in women with breast and ovarian cancer.” (NEW)
“Parasite proteins prompt immune system to fight off ovarian tumors in mice”, ScienceDaily (July 22, 2016), “Scientists identified the specific proteins secreted by the parasite Toxoplasma gondii that cause the immune system in mice to attack established ovarian tumors.” (NEW)
“Preventive procedure for ovarian cancer adopted without adverse surgical outcomes”, ScienceDaily (July 12, 2016), “A surgical procedure recommended to reduce the future risk of ovarian cancer has been successfully implemented throughout in Northern California without a change in surgical outcomes.” (NEW)
“Discovery of new ovarian cancer signaling hub points to target for limiting metastasis”, ScienceDaily (July 10, 2016), “Researchers have found a previously undiscovered pathway through which ovarian cells can be transformed into cancer cells, one they think provides an excellent opportunity for targeting by new drugs, which, when combined with others now in development, may be able to stave off metastatic disease. ” (NEW)
“New imaging technique could identify additional ovarian tumors not visible to surgeons' eyes”, ScienceDaily (June 15, 2016), “A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery, say researchers. ” (NEW)
“Breast, ovarian cancer may have similar origins, study finds”, ScienceDaily (May 23, 2016), “While breast cancer is the most common cause of cancer death in women worldwide, ovarian cancer also is a significant source of mortality as the fifth leading cause of cancer death among women. These facts reflect the continued need for further understanding and innovation in cancer treatment. A new study describes a new concept of how these two cancers may evolve in a similar way and may eventually lead to more effective therapies for both. ” (NEW)
“Research points to possible new prevention strategies for ovarian cancer”, ScienceDaily (May 24, 2016), “The discovery of early changes in the cells of the Fallopian tubes of women carrying the BRCA genetic mutation could open the way for new preventative strategies for ovarian cancer, reducing the need for invasive surgery, according to new research. ” (NEW)
“Immune cells help reverse chemotherapy resistance in ovarian cancer”, ScienceDaily (May 20, 2016), “New research explains why ovarian cancer becomes resistant to chemotherapy. The findings suggesting the potential to harness immunotherapy as a future treatment option. ” (NEW)
“Engineered ovary implant restores fertility in mice“, ScienceDaily (April 1, 2016), “Scientists created a prosthetic ovary using a 3-D printer -- an implant that allowed mice that had their ovaries surgically removed to bear live young.”
“Pathologists identify new potential target in ovarian serous cancer“, ScienceDaily (March 18, 2016), “Patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival, research shows.”
“New gene identified as cause, early indicator of breast cancer“, ScienceDaily (March 18, 2016), “When mutated, a gene known for its ability to repair DNA, appears to instead cause breast cancer, scientists report. Mutations of the gene are known to be present in both early onset breast and ovarian cancer. Now scientists have shown that the stem, or progenitor cells, which should ultimately make healthy breast tissue, can also have GT198 mutations that prompt them to instead make a perfect bed for breast cancer.”
“How a master regulator in ovarian cancer can go from helpful to harmful“, ScienceDaily (February 11, 2016), “Scientists have defined the role of how a master genomic organizer influences the behavior of these ovarian-associated dendritic cells, revealing a previously unseen way in which cancer is able to manipulate our immune system.”
“Research uncovers more inherited genetic mutations linked to ovarian cancer“, ScienceDaily (February 10, 2016), “Previous research has established a link between genetic mutations in the BRCA1 and BRCA2 genes to an increased risk of developing ovarian, fallopian tube or peritoneal cancer in women. A recent publication documents the efforts of a team of researchers to determine if inherited genetic mutations other than BRCA1 and BRCA2 can also put a woman at risk of developing these diseases.”
“Preventive surgery for women at high risk of breast, ovarian cancer”, ScienceDaily (February 3, 2016), “A new article provides an in-depth look at the issues associated with the care of women in families with hereditary breast and ovarian cancer syndrome who have not yet developed cancer themselves.”
“Sparing ovaries, removing fallopian tubes may cut cancer risk, but few have procedure“, ScienceDaily (February 1, 2016), “During hysterectomies for non-cancerous conditions, removing both fallopian tubes while keeping the ovaries may help protect against ovarian cancer and preserve hormonal levels, but few women receive this surgical option, according to a new study.”
“Up to 50 percent of women with advanced-stage ovarian cancer could be cured with one treatment model, expert argues“, ScienceDaily (January 20, 2016), “Up to half of women with advanced-stage ovarian cancer might be cured, compared to the current 20 percent survival rate, argues a scientist, who calls for a new standard of treatment for women with late-stage ovarian cancer.”
“Stopping ovarian cancer in its tracks: Antibody may help patients heal themselves“, ScienceDaily (December 1, 2015), “In a first, researchers show the potential a PD-1 antibody, nivolumab, has in fighting the disease. Nivolumab, an inhibitory antibody for PD-1, has shown efficacy in several types of malignancies including melanoma, kidney cancer, and non-small cell lung cancer.”
“Insights to how ovarian cancer grows, and potential to stop it“, ScienceDaily (November 30, 2015), “Can any cancer cell form another tumor, or is it only select cancer stem cells that give rise to new cancer cells? The answer, a new study finds, is both.”
“Previous oral contraceptive use associated with better outcomes in patients with ovarian cancer, study finds“, ScienceDaily (November 11, 2015), “Patients who develop ovarian cancer appear to have better outcomes if they have a history of oral contraceptive use, according to a study."
“Scientists discover genetic mechanism essential to ovary development“, ScienceDaily (November 5, 2015), “Scientists have announced a discovery that is expected to allow doctors to diagnose a disease causing infertility and lack of puberty in women, with implications for the development of future treatment options. The characterization of the Nup107 gene and discovering its function in ovarian development will provide a greater understanding of how signaling between the cytoplasm and the nucleus is uniquely involved in ovarian development.”
“CK5 marks cisplatin-resistant ovarian cancer“, ScienceDaily (November 4, 2015), “Protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin, new research confirms.”
“New research shows ovarian transplants appear to be safe, effective“, ScienceDaily (October 6, 2015), “Women who have ovarian tissue removed, stored and then transplanted back to them at a later date have a good chance of successfully becoming pregnant, according to a review of the largest series of ovarian transplants performed worldwide.”
“Number of cancer gene tests increases five-fold thanks to improved availability: making prevention easier “, ScienceDaily (September 28, 2015), “Mutations in the BRCA 1 and BRCA 2 genes are very likely to lead to a form of cancer in people who have them. These mutations can be detected using a genetic test. The introduction of a new drug has improved treatment options and this, coupled with increased awareness and improved access, increased the number of genetic tests carried out at one hospital last year by a factor of five. As a result, more at-risk patients are picked up and early prevention measures can be commenced.”
“Advance in photodynamic therapy offers new approach to ovarian cancer“, ScienceDaily (August 13, 2015), “Researchers have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors."
“Multigene panel testing for hereditary breast/ovarian cancer risk assessment“, ScienceDaily (August 13, 2015), “Multigene testing of women negative for BRCA1 and BRCA2 found some of them harbored other harmful genetic mutations, most commonly moderate-risk breast and ovarian cancer genes and Lynch syndrome genes, which increase ovarian cancer risk, according to an article.”
“Largest Ever Ovarian Cancer Trial Suggests That Screening Reduces Mortality, But Longer Follow-Up is Needed”, ScienceDaily (December 20, 2015), “One of the largest ever randomised trials has concluded that ovarian cancer screening may reduce ovarian cancer mortality by an estimated 20% after follow up of up to 14 years. Longer follow-up is needed to determine the ultimate mortality reduction and if screening the general population is cost effective."
“Researchers Find Experimental Drug Can Help Fight Debilitating Side Effect of Ovarian Cancer”, ScienceDaily (November 17, 2015), “Women who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen. A drug that inhibits a receptor called the Colony-Stimulating-Factor-1 Receptor, or CSF1R, reduces ascites with minimal side effects, new research shows.”
“Healthy Diet May Reduce Risk of Ovarian Cancer in African-American Women”, ScienceDaily (November 13, 2015), “A healthy diet may reduce the risk of ovarian cancer in African-American women, according to new data."
“Mechanism Discovered That Could Lead to Better Ovarian Cancer Treatment”, ScienceDaily (October 26, 2015), “Resistance to chemotherapy is a major problem for those suffering from ovarian cancer -- a problem that prevents a cure from a disease dubbed the 'silent killer.' Now researchers are giving patients new hope with recent findings that help pinpoint the mechanisms causing chemoresistance."
“Treatment-Free Intervals in Ovarian Cancer not Linked to Initial Response” ScienceDaily (September 30, 2015), “Three-quarters of women treated for ovarian cancer face relapse of their disease. And while those who respond well to initial therapy do tend to survive longer, they require additional treatment for recurring cancer just as frequently as other women whose initial treatment response was not so pronounced. This is a key conclusion of new research that contributes new information about the dynamics of recurrent ovarian cancer."
“Multigene panel testing for hereditary breast/ovarian cancer risk assessment”, ScienceDaily (August 13, 2015), “Multigene testing of women negative for BRCA1 and BRCA2 found some of them harbored other harmful genetic mutations, most commonly moderate-risk breast and ovarian cancer genes and Lynch syndrome genes, which increase ovarian cancer risk, according to an article."
“Long-term ovarian cancer survival higher than thought”, ScienceDaily (August 6, 2015), “Combing data collected on thousands of California ovarian cancer patients, researchers have determined that almost one-third survived at least 10 years after diagnosis.”
“Combination therapy may be more effective against the most common ovarian cancer”, ScienceDaily (August 3, 2015), “High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery. Now a team of researchers has discovered that a subset of tumor cells that don’t produce the protein CA125, a biomarker used to test for ovarian cancer, has an enhanced ability to repair their DNA and resist programmed cell death — which allows the cells to evade the drug and live long enough to regrow the original tumor.”
“Anti-inflammatory drug acts against ovarian cancer, scientists find”, ScienceDaily (July 28, 2015), A non-steroidal anti-inflammatory drug (NSAID) called ketorolac helped women with ovarian cancer to survive longer, researchers report. Ketorolac, marketed as Toradol®, is approved for clinical use in the United States for pain after surgery.”
“Scientists solve breast, ovarian cancer genetic mystery”, ScienceDaily (July 16, 2015), “Scientists have solved a decades-old mystery and helped to unravel the genetic cause of some breast and ovarian cancers, according to new research. Following a five-year study in nematode worms, researchers have uncovered how key proteins can switch on a protein called RAD51, allowing it to repair cancer-causing DNA damage in cells.”
“Leisure time sitting linked to higher risk of specific cancers”, ScienceDaily (July 13, 2015), “Spending more leisure time sitting was associated with a higher risk of total cancer risk in women, and specifically with multiple myeloma, breast, and ovarian cancers, according a new study.”
“New drug combo could make cancer more sensitive to chemo”, ScienceDaily (July 13, 2015), “Combining chemotherapy with new drugs that target a protein that helps cancer cells to withstand chemotherapy could drastically improve treatment, according to new research.”
“Researchers discover how ovarian cancer halts body's natural defense against tumor”, ScienceDaily (June 11, 2015), “Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, scientists report. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.”
“ADAMTS family of genes may be the next 'thing' in ovarian cancer treatment”, ScienceDaily (June 11, 2015), “There is the Addams Family. And then there is the ADAMTS family. While one is mindless entertainment, the latter may prove to be a new genetic avenue for designing ovarian cancer treatment, scientists report.”
“Scientists discover new molecules that kill cancer cells and protect healthy cells”, ScienceDaily (May 13, 2015), “Molecules could treat cervical, breast, ovarian, and lung cancers, new research in mice suggests. Scientists have found a new family of molecules that kill cancer cells and protect healthy cells, which could be used to treat a number of different cancers. Research shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.”
“Chemo before surgery benefits patients with advanced ovarian cancer“, ScienceDaily (May 19, 2015), “Women with advanced ovarian cancer have fewer side effects and tend to have a better quality of life if given chemotherapy before surgery, according to a study. Delaying surgery also reduced the amount of time the patient spent in the hospital after surgery.”
“Biomarker may boost ovarian cancer chemotherapy response“, ScienceDaily (May 20, 2015), “A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer. Chemoresistance is a major challenge in cancer treatment and this study may provide a means to overcome resistance, the researchers say.”
“Ovarian cancer-specific markers set the stage for early diagnosis, personalized treatments“, ScienceDaily (May 25, 2015), “Six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells have been identified by scientists, opening up the possibility that they could be used to diagnose early-stage ovarian cancer. What's more, several of the mRNA isoforms code for unique proteins that could be targeted with new therapeutics.”
“Study could explain why ovarian cancer treatments fail“, ScienceDaily (May 27, 2015), “Ovarian cancer cells can lock into survival mode and avoid being destroyed by chemotherapy, an international study reports. The research used whole genome sequencing to analyse tumor DNA samples from 91 patients with high-grade serous ovarian cancer (HGSC)."
”Seeking new targets for ovarian cancer treatment”, ScienceDaily (April 19, 2015), “Identifying molecular changes that occur in tissue after chemotherapy could be crucial in advancing treatments for ovarian cancer, according to research from Magee-Womens Research Institute and Foundation and the University of Pittsburgh Cancer Institute presented today at the American Association for Cancer Research Annual Meeting 2015."
”New method increases accuracy of ovarian cancer prognosis and diagnosis”, ScienceDaily (April 15, 2015), “Scientists have uncovered patterns of DNA anomalies that predict a woman's outcome significantly better than tumor stage. In addition, these patterns are the first known indicator of how well a woman will respond to platinum therapy. The patterns were discovered by using a new mathematical technique in the analysis of DNA profiles from the Cancer Genome Atlas, a national database containing data from hundreds of ovarian cancer patients.”
”Risk of breast and ovarian cancer may differ by type of BRCA1, BRCA2 mutation”, ScienceDaily (April 7, 2015), “Researchers have identified mutations that are associated with significantly different risks of breast and ovarian cancers. Authors say the results -- which show that some mutations confer higher risks of breast cancer, while other mutations show higher risks of ovarian cancer -- may lead to more effective cancer risk assessment, care and prevention strategies for health care providers and carriers."
“Cancer-killing virus plus chemotherapy drug might treat recurrent ovarian cancer”, ScienceDaily (November 13, 2014), “In six out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and five-year survival is only 27 percent. A new study suggests that a cancer-killing virus combined with a chemotherapy drug might safely and effectively treat advanced or recurrent forms of the disease.”
“Ovarian cancer patients may benefit from pelvic radiotherapy”, ScienceDaily (November 18, 2014), “Pelvic radiotherapy (RT) may help treat a rare form of ovarian cancer that can recur in women after surgery and chemotherapy, researchers report. The study evaluated 56 patients with ovarian clear cell adenocarcinoma (CCA), an aggressive form of ovarian cancer that is more likely to be resistant to chemotherapy and to have a poorer prognosis than other forms of this disease.”
“Olaparib shows success in tumor response rate for patients with BRCA-related cancers”, ScienceDaily (November 6, 2014), “Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research. The positive response provides new hope for patients with ovarian, breast, pancreatic and prostate cancers whose conditions have not responded to standard therapies.”
“Ovarian cancer: New test can help doctors choose best treatment”, ScienceDaily (October 15, 2014), “A new test to help doctors diagnose ovarian tumors and choose the most appropriate treatment has been devised by researchers. Successful treatment depends in part on accurately identifying the type of tumor, but this can be difficult. The new test can discriminate between benign and malignant tumors, and identify different types of malignant tumor, with a high level of accuracy.”
“Ovarian cancer often arises from precursor endometriosis“, By: BRUCE JANCIN, Oncology Practice Digital Network (October 2, 2014), “Mounting evidence suggests that identification and complete surgical removal of endometriosis reduce the risk of several histologic types of ovarian cancer. So when a woman visits her primary care physician for pelvic pain or vaginal bleeding that might be due to endometrial pathology, or a general surgeon finds asymptomatic endometriosis during pelvic surgery, these encounters provide an opportunity for preventive intervention..."
“Genetic pathway can slow spread of ovarian cancer”, ScienceDaily (June 17, 2014), “Research into the origins of ovarian cancer has led to the discovery of a genetic pathway that could slow the spread of the cancer. The discovery is in part due to research into the genetics of humans' most distant mammalian relative, the platypus.”
“Clinical trial analysis suggests drug combination may be highly effective in recurrent ovarian cancer”, National Institutes of Health (June 2, 2014), “Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology meeting in Chicago. This is the first ovarian cancer study to use a combination of drugs that could be taken orally. The drugs were tested in a phase I combination study followed by a randomized phase 2 trial sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health.”
“More patients with ovarian cancer are receiving chemotherapy before surgery”, ScienceDaily (May 30, 2014), “The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis. Having government-run health insurance -- Medicaid or Medicare -- also increased a woman's odds of undergoing chemotherapy before surgery. In contrast, race and location did not appear to influence her likelihood of receiving neoadjuvant therapy.”
“Significant side effects experienced by BRCA mutation carriers following cancer risk-reducing surgical procedure”, ScienceDaily (May 30, 2014), “The majority of women with cancer causing BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following prophylactic removal of their Fallopian tubes and ovaries -- a procedure known as risk-reducing salpingo-oophorectomy (RRSO) -- according to results of a new study."
“Few women at high-risk for hereditary breast, ovarian cancer receive genetic counseling”, ScienceDaily (May 8, 2014), “Mutations in the BRCA1 and BRCA2 genes account for nearly 25 percent of hereditary breast cancers and most hereditary ovarian cancers, yet a study by cancer prevention and control researchers suggests an alarmingly small amount of women who qualify for BRCA genetic counseling actually receive the services. Additionally, they found that a significant proportion of women with a family history of breast and ovarian cancer underestimate their risk.”
“Glutamine ratio is key ovarian cancer indicator”, ScienceDaily (May 5, 2014). “An analysis of the metabolic profiles of hundreds of ovarian tumors has revealed a new method for tailoring treatments for ovarian cancer and for assessing whether ovarian cancer cells have the potential to metastasize.”
“Decreasing chemoresistance in ovarian cancer”, ScienceDaily (May 2, 2014), “Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients, researchers say.“
“Potential new strategy to treat ovarian cancer discovered”, ScienceDaily (April 28, 2014), “A potential new strategy to treat ovarian cancer has been identified by researchers. Recently developed drugs have increased patient survival rates by targeting a tumor's blood vessels that supply essential nutrients and oxygen to cancer cells.”
“Attacking cancer indirectly: Generating immunity against tumor vessel protein in mouse study”, ScienceDaily (April 25, 2014), “A novel DNA vaccine is being trialed to kill cancer, not by attacking tumor cells, but targeting the blood vessels that keep them alive. The vaccine also indirectly creates an immune response to the tumor itself, amplifying the attack by a phenomenon called epitope spreading.”
“Potential Target For Epithelial Ovarian Cancer Treatment Identified”, ScienceDaily (April 7, 2014), “Researchers who are investigating the biological mechanisms behind metastatic epithelial ovarian cancer recently found that an enzyme called focal adhesive kinase (FAK) can play a critical -- and previously unstudied -- role in the growth and spread of the disease.”
“Father's Age At Birth May Affect Daughter's Cancer Risk”, ScienceDaily(April 7, 2014), “A parent’s age at birth, particularly a father’s age, may affect the adult-onset cancer risk for daughters — especially for breast cancer.”
“Scaffolding Protein Promotes Growth, Metastases Of Epithelial Ovarian Cancer”, ScienceDaily (April 6, 2014), “A scaffolding protein responsible for regulating signaling pathways in the cell promotes the growth and spread of epithelial ovarian cancer, research has determined.”
“Combining Cell Replication Blocker With Common Cancer Drug Kills Resistant Tumor Cells“, ScienceDaily (April 4, 2014), “Researchers have found that an agent that inhibits mitochondrial division can overcome tumor cell resistance to a commonly used cancer drug, and that the combination of the two induces rapid and synergistic cell death. Separately, neither had an effect."
“Disease-Free Survival Estimates For Ovarian Cancer Improve Over Time”, ScienceDaily (April 4, 2014), “The probability of staying disease-free improves dramatically for ovarian cancer patients who already have been disease-free for a period of time, and time elapsed since remission should be taken into account when making follow-up care decisions, according to a study. This measure is known as conditional disease-free survival.”
“Uncommon Genetic Variations May Contribute To Ovarian Cancer Risk”, ScienceDaily (April 4, 2014), “Variations in a woman’s genome may contribute to her risk of developing ovarian cancer. Researchers have discovered uncommon variants in new regions of the genome that influence ovarian cancer risk.”
“Jamming A Protein Signal Forces Cancer Cells To Devour Themselves”, ScienceDaily (April 3, 2014), “Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research, a study shows."
“Targeted Treatment For Ovarian Cancer Discovered”, ScienceDaily (February 19, 2014), “Researchers have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy.”
“Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women”, U.S. Preventive Services Task Force (February 18, 2014), A "final recommendation statement" by the U.S. Preventive Services Task Force."
“Best Drug For Ovarian Cancer Picked With Use Of Genetics”, ScienceDaily (February 18, 2014), “There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. A sophisticated model of ovarian cancer genetics was used to match the right tumor with the right drug in a recent study. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.”
“Regular Aspirin Use May Reduce Ovarian Cancer Risk: Study”, ScienceDaily (February 6, 2014), “Women who take aspirin daily may reduce their risk of ovarian cancer by 20 percent, according to a study. However, further research is needed before clinical recommendations can be made.”
“One In Five Women With Ovarian Cancer Has Inherited Predisposition”, ScienceDaily (January 22, 2014), “A new study conservatively estimates that one in five women with ovarian cancer has inherited genetic mutations that increase the risk of the disease.”
"Biological Therapy Improves Survival in Women with Recurrent Ovarian Cancer", ScienceDaily (September 30, 2013), "Women with ovarian cancer that has recurred after chemotherapy have survived longer after treatment with a biological therapy called cediranib, according to new results to be presented at the 2013 European Cancer Congress."
"Women can Lower Their Risk for Gynecologic Cancer", ScienceDaily (September 16, 2013), "From losing weight to knowing their family history, there are several things women can do to lower their risk of developing certain types of cancer, and improve their chances for survival if they do develop one of them."
"Versatile microRNAs Choke off Cancer Blood Supply, Suppress Metastasis", ScienceDaily (September 11, 2013), "A family of microRNAs blocks cancer progression and metastasis by stifling a tumor’s ability to weave new blood vessels to support itself, researchers have reported."
"Some Immune Cells Appear to Aid Cancer Cell Growth", ScienceDaily (September 5, 2013), "The immune system is normally known for protecting the body from illness. But a subset of immune cells appear to be doing more harm than good."
"Large Study Reveals Increased Cancer Risks Associated with Family History of the Disease", ScienceDaily (July 24, 2013), "A family history of cancer increases the risk of other members of the family developing not only the same cancer but also a different (discordant) cancer, according to a large study of 23,000 people in Italy and Switzerland."
"Cancer Researchers Discover how BRCA Mutation Starts Breast, Ovarian Cancers", ScienceDaily (July 15, 2013), "Scentists have solved a key piece in the puzzle of how BRCA1 gene mutations specifically predispose women to breast and ovarian cancers."
"Newly Discovered Hormone Makes Ovaries Grow", ScienceDaily (May 30, 2013), “A newly discovered hormone produced by the eggs of human females may improve the effectiveness of current fertility treatments for women and possibly lead to entirely new treatments altogether. Researchers have identified a new hormone called "R-spondin2" that promotes follicle development and stimulates ovary growth.”
"How Gold Nanoparticles Can Help Fight Ovarian Cancer", ScienceDaily (May 21, 2013), “Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells.”
"Markers Related to Ovarian Cancer Survival and Recurrence Identified", ScienceDaily (April 30, 2013), “Animal sciences researchers have identified biomarkers that are used to determine ovarian cancer survival and recurrence and shown how the interactions between these biomarkers affect these outcomes.”
“New Type of Experimental Drug Active in Platinum-Resistant Ovarian Cancers”, ScienceDaily (April 7, 2013), “The antibody-drug conjugate DMUC5754A, a novel member of a relatively new class of drugs, showed activity in women with ovarian cancer, even those with hard-to-treat, platinum-resistant disease, in a phase I trial.”
“Targeted Toxin Active in Platinum-Resistant Ovarian Cancers”, ScienceDaily (April 7, 2013), ”Researchers have found that a novel antibody-guided drug achieves responses in platinum drug-resistant ovarian cancer.”
“Five Genetic Variations Increase Risk of Ovarian Cancer”, ScienceDaily (March 27, 2013), “Scientists have found five new regions of the human genome that are linked to increased risks for developing ovarian cancer.”
“Functional Ovarian Tissue Engineered in Lab”, ScienceDaily (March 26, 2013), “Proof-of-concept study suggests the possibility of engineering artificial ovaries in the lab to provide a more natural option for hormone replacement therapy for women.”
"Bathing Abdomen in Chemotherapy Gives Ovarian Cancer Patients Better Chance of Survival", ScienceDaily (March 9, 2013), "A recent study suggests that patients with advanced ovarian cancer who undergo intensive treatment with chemotherapy that bathes the abdomen are significantly more likely to live longer than those who receive standard intravenous (IV) chemotherapy."
"Breakthrough in ovarian cancer: Selumetinib", ScienceDaily (February 14, 2013), "Researchers have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib."
"Nanotech'ed RNA drug reduces ovarian cancer tumors by 83 percent", ScienceDaily (February 12, 2013), "By loading fragile RNA into silicon nanoparticles, researchers have found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue."
"DNA-repairing protein may be key to preventing recurrence of some cancers", ScienceDaily (January 28, 2013), "Just as the body can become resistant to antibiotics, certain methods of killing cancer tumors can end up creating resistant tumor cells. But a professor has found a protein present in several types of cancer, including breast and ovarian cancer, which could be helpful in preventing tumors from coming back."
"High blood calcium levels may indicate ovarian cancer", ScienceDaily (January 23, 2013), "A new study reports that high blood calcium levels might predict of ovarian cancer, the most fatal of the gynecologic cancers."
"Study shows promise of molecular screening for gynecologic cancers, commentary writers state", ScienceDaily (January 9, 2013), "A new study that proposes a three-in-one test for gynecologic cancers underscores the promise of molecular screening for early detection of endometrial and ovarian cancers, but also suggests that such tests are not yet ready for clinical use. Andrea Myers, MD, PhD, of Dana-Farber Cancer Institute, a co-author of the commentary on the study, says the test is an important step in that direction."
"Natalie Cosman, 8-Year Old Diagnosed With Ovarian Cancer, Is Now Cancer-Free", by Sara Gates, from The Huffington Post (September 17, 2012), read this heartwarming story about a little girl's ovarian cancer diagnosis and fight to beat ovarian cancer. It is notable that the statement, "Now, more and more cases are coming up with little girls." is made in this article. Parents and health care providers need to keep that in mind.
"Discovery Leads to New Hope Against Ovarian Cancer", ScienceDaily (October 3, 2012), "Scientists at USC have discovered a new type of drug for the treatment of ovarian cancer that works in a way that should not only decrease the number of doses that patients need to take, but also may make it effective for patients whose cancer has become drug-resistant."
"Treating Ovarian Cancer: New Pathways Through Genetics", ScienceDaily (September 24, 2012), "A new discovery that sheds light on the genetic make up of ovarian cancer cells could explain why some women survive longer than others with this deadly disease."
"Study Reveals Genomic Similarities Between Breast Cancer and Ovarian Cancer", NIH News (September 23, 2012), "One subtype of breast cancer shares many genetic features with high-grade serous ovarian cancer, a cancer that is very difficult to treat, according to researchers supported by the National Institutes of Health."
"PARP Inhibitors May Have Clinical Utility in HER2-Positive Breast Cancers", ScienceDaily (September 17, 2012), "Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive breast cancers."
"Mechanisms of Acquired Chemoresistance in Ovarian Cancer Identified", ScienceDaily (April 15, 2012), Multiple ovarian cancer genomes in an individual patient and the absence or downregulation of the gene LRP1B associated with development of chemoresistance in women with the high-grade serous cancer subtype of ovarian cancer whose disease recurs after primary treatment.
"New Treatment Option to Reduce Metastasis in Ovarian Cancer", ScienceDaily (January 26, 2011), "A paper published January issue of the journal Nanomedicine could provide the foundation for a new ovarian cancer treatment option -- one that would use an outside-the-body filtration device to remove a large portion of the free-rotating cancer cells that often create secondary tumors."
"Glow-in-the-Dark Cells Help Find Ovarian Cancer", New study sheds light on how doctors can look at ovarian tumors. (click title to watch this video on CBS.com)
"Awareness Effort Raises Profile of Ovarian Cancer", Local ovarian cancer story on CNN Health Minute
By Val Willingham, CNN Medical Producer
Watch the ABC News video, "Cancer Breakthrough".
Read the CBS News article, "Ovarian Cancer Tied to Fertility Treatments: Cause for Alarm?", by Ryan Jaslow.
"Screening Does Not Reduce Deaths from Ovarian Cancer for the General Population", from cancer.net (05/18/2011).
"Long-Term Treatment with Olaparib May Help Treat Recurrent Ovarian Cancer", from cancer.net.
"Cabozantinib Helps Manage Several Advanced Cancers and Shrink Bone Metastases "(05/18/2011), from cancer.net.
"Genetic Variations Identify Patients Sensitive to Nerve Damage from Chemotherapy"(05/18/2011), from cancer.net.
Copyright 2022 Delaware Ovarian Cancer Foundation. All rights reserved.
Delaware Ovarian Cancer Foundation
701 Sweetleaf Drive
Wilmington, DE 19808
United States
ph: 302-998-6889
docf5k